Innovotech Receives NRC IRAP Funding to Advance Antimicrobial Testing for Medical Devices

Innovotech Inc. (TSX Venture Exchange:IOT; OTCQB:IOTCF) announced that its subsidiary, Innovotech Labs Corporation, will receive advisory services and research and development funding of up to $234,000 CAD from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). The funding supports the development of new antimicrobial testing services tailored for medical devices such as catheters, implants, and wound dressings.

The new testing methods align with evolving international regulatory standards and address medical device manufacturers' needs concerning microbial proliferation, biofilm formation, and translocation. This initiative builds on foundational work from the previous year, advancing it into more robust, fit-for-purpose testing. As customer programs expand, manufacturers increasingly require advanced testing that better reflects real-world use and provides clearer decision-making data. Strengthening these capabilities will broaden Innovotech's service offerings, support regulatory readiness, and help customers demonstrate device safety and performance more effectively.

Craig Milne, CEO of Innovotech, stated, "This NRC IRAP support will help us to deepen our technical bench, problem solve for our customers and deliver solutions that reduce infections and complications for better health outcomes. It also positions us to meet rising client demand with higher-complexity testing and stronger technical support as standards and expectations continue to evolve."

Innovotech Inc. is a leading life sciences services and technology company specializing in contract research, analytical, and microbial testing within regulated healthcare markets. The company is recognized for its expertise in biofilm science and antimicrobial testing, providing advanced laboratory services that support medical device, pharmaceutical, and industrial product development. Innovotech combines scientific expertise with proprietary methodologies, including the widely used MBEC Assay® platform for high-throughput antimicrobial and antibiotic testing. Operating through ISO-certified and GMP-accredited laboratories, Innovotech supports clients across multiple sectors and geographies, delivering reliable data aligned with regulatory expectations from bodies such as the U.S. Food and Drug Administration and Health Canada. More information is available at https://www.innovotech.ca.

This funding from NRC IRAP underscores the importance of antimicrobial testing in reducing healthcare-associated infections and improving patient outcomes. By enhancing testing capabilities, Innovotech aims to support medical device manufacturers in meeting stringent regulatory requirements and ensuring product safety. The development of these services is expected to have significant implications for the medical device industry, potentially leading to more effective infection control and better health outcomes for patients.

The original press release can be accessed at https://www.newmediawire.com.